

A different kind of imaging: Optogenetics and novel substance abuse treatments

Antonello Bonci, MD

NIDA/NIH

NIDA Intramural Program



NATIONAL INSTITUTE ON DRUG ABUSE

INTRAMURAL RESEARCH PROGRAM

Office of the Clinical Director **HN646**
Marcus Heilig, M.D. Clinical Director

Clinical Directors Office **Pharmacy**

Markus Heilig, M.D. Federal Paul Na, P.D. Federal
Clinical Director *Chief Pharmacist*

Agnes Coffay, M.D. Federal Arum Jung, P.D. Contractor
Deputy Director (Acting) *Deputy Chief Pharmacist*

MMG Recruitment Services

Margaret Kroen MMG
Project Manager

Office of the Scientific Director **HN641**
Anto Bonci, M.D. Scientific Director

Scientific Directors Office

Anto Bonci, M.D. Federal
Scientific Director *HN641*

Amy Newman, Ph.D. Federal
Deputy Director

Michelle, Leff, M.D, M.B.A. Federal
Chief of Staff

Animal Care Section Federal
 Kyle Stump, DVM, DACLAM
Animal Program Director

Optogenetics & Transgenic Technology Core Federal
 Brandon Harvey., Ph.D.
Director

Office of Education & Career Development Federal
 Stephen Heishman., Ph.D.
Director

Administrative Management Branch **HN642**
Susan Harrelson, M.P.P. Branch Chief

Administrative Unit **Biomedical Informatics**

Susan Harrelson, M.P.P. Federal Massoud Vahabzadeh, Ph.D. Fed
Chief *Chief*

Thomas Haines, M.S. Federal
Deputy Chief

Budget and Finance Federal **Procurement** Federal
 Tim Kirkendall *Budget Analyst* Sheila Zichos *Procurement Chief*

Visual Media JHBMC **Technical Services JHBMC** JHBMC
 Thomas Wynn *Supervisor* David Strappelli, M.B.A. *Program Manager*

Occupational Safety CSS
 Delores Wilson (Acting) *Program Manager*

Molecular Targets & Medications Discovery **HN645**
Amy Newman, Ph.D. Branch Chief

Psychobiology Section Federal
 Jonathan Katz, Ph.D. *Chief* *HN6452*

Medicinal Chemistry Section Federal
 Amy Newman, Ph.D. *Chief* *HN6454*

CNS Receptor – Receptor Interaction Unit Federal
 Sergi Ferre, Ph.D.

Molecular Neuropsychiatry **HN64E**
Jean Lud Cadet, M.D. Branch Chief

Molecular Neuropsychiatry Section Federal
 Jean Lud Cadet, M.D. *Chief*

Neural Protection & Regeneration Section Federal
 Yun Wang, M.D. *Chief*

Neuroimaging **HN647**
Elliot Stein, Ph.D. Branch Chief

FMRI – Stein Section Federal
 Elliot Stein, Ph.D. *Chief*

FMRI –Yang Section Federal
 Yihong Yang, Ph.D. *Chief*

Chemical Biology **HN64G**
Kenner Rice, Ph.D. Branch Chief

Drug Design & Synthesis Section Federal
 Kenner Rice, Ph.D. *Chief* *HN64G2*

Neuropsychopharmacology Section Federal
 Eliot Gardner, Ph.D. *Chief* *HN64G3*

Translational Pharmacology Section Federal
 Vacant *Chief* *HN64G4*

Behavioral Neuroscience **HN64D**
Yavin Shaham, Ph.D. Branch Chief

Behavioral Neuroscience Section Federal
 Roy Wise, Ph.D. *Chief* *HN64D2*

Neurocircuitry Motivation Section Federal
 Satoshi Ikemoto, Ph.D. *Chief* *HN64D4*

Preclinical Pharmacology Section Federal
 Steve Goldberg, Ph.D. *Chief* *HN64D3*

Neurobiology of Relapse Section Federal
 Yavin Shaham, Ph.D. *Chief*

Molecular Mechanisms of Behavior Unit Federal
 Bruce Hope, Ph.D.

Cellular Neurobiology **HN64C**
Geoff Schoenbaum M.D. Branch Chief

Development & Plasticity Section Federal
 William Freed, Ph.D. *Chief* *HN64C2*

Electrophysiology Section Federal
 Carl Lupica, Ph.D. *Chief*

Synaptic Plasticity Section Federal
 Anto Bonci, M.D. *Chief* *HN64C6*

Behavioral Neurophysiology Neuroscience Section Federal
 Geoff Schoenbaum, M.D. *Chief* *HN64C2*

Integrative Neuroscience **HN64H**
Marisela Morales, Ph.D. Branch Chief

Integrative Neuroscience Section Federal
 Vacant, Ph.D. *Chief* *HN64H2*

Cellular Pathobiology Section Federal
 Tsung-Ping Su, Ph.D. *Chief* *HN64H3*

Structural Biology Unit Federal
 Amina Woods., Ph.D.

Multi-Photon Core Facility Federal
 Carl Lupica, Ph.D. *Acting Chief*

Neuronal Networks Section Federal
 Marisela Morales, Ph.D. *Chief* *HN64C5*

Histology Core Facility Federal
 Marisela Morales, Ph.D. *Chief* *HN64C5*

Clinical Pharmacology & Therapeutics **HN644**
Kenzie Preston, Ph.D. Branch Chief

Treatment Section Federal
 Kenzie Preston, Ph.D. *Chief* *HN6442*





Chemistry and Drug Metabolism Section Federal
 Marilyn Huestis, Ph.D. *Chief* *HN6444*

Nicotine Psychopharmacology Section Federal
 Stephen Heishman, Ph.D. *Chief* *HN6445*

Molecular Neurobiology **HN64B**
George Uhl, M.D. Branch Chief

Molecular Neurobiology Section Federal
 George Uhl, M.D. *Chief* *HN64B*

The hallmark of the NIDA IRP is to perform high risk, long term, cutting edge science translating to improve public health through medication and therapy to treat addiction






Any addictive behavior depends on changes in electrical activity of specific brain regions



Genetic background

Environmental stimuli

No drugs




Any addictive behavior depends on changes in electrical activity of specific brain regions



Genetic background
Environmental stimuli


No drugs





Drugs of abuse



Δ Synapses
Ion channels




Any addictive behavior depends on changes in electrical activity of specific brain regions




Light sensitive proteins

Channelrhodopsin-2 from *Chlamydomonas reinhardtii* (2005)




Halorhodopsin from *Natronomonas pharaonis* (2006)



The channelrhodopsin is packaged into a virus

AAV

AAV-CaMKII α -ChR2-EYFP:




Specificity

visibility

Bidirectional activity

Mapping one pathway at the time, to:

1. determine the role of each pathway in reward-related behaviors and drug exposure
2. determine the relationship between strength of each synaptic inputs and behavioral output



A novel use of optogenetics

1. Does “compulsive” cocaine self-administration induce hypofrontality in the prelimbic portion of the PFC?
1. Can we override PFC hypoactivity (and drug taking) by using **optogenetic** stimulation of the PFC

What is the best model of compulsive drug use in rodents


- Limitations of extinction-reinstatement model
- **Compulsion:** Drug use is continued despite incurring into negative consequence - **introducing cost (shock) to self-administration paradigm.**

After Deroche-Gamonet et al., Science (2004)

Vanderschuren et al., Science (2004)




Modified self-administration paradigm

1. Rats are trained to self-administer cocaine on a seek-take chain schedule (about 2 months) *with progressively longer Random Intervals*.
2. At the very end of training, rats receive 4 sessions of non-contingent foot shock in 30% of trials






1. Rats are divided into non-compulsive and compulsive groups

shock sensitive





Shock-resistant




Hypofrontality in prelimbic neurons after long-access cocaine self-administration

In vivo whole-cell recording in anesthetized rat, targeting prelimbic region



Naive







100 pA
10 sec

Cocaine



100 pA
10 sec

Long-access to cocaine decreases excitability of deep-layer cortical neurons




Hypothesis:


Optogenetic activation of the prelimbic area
could reduce compulsive cocaine seeking

ChR2 method

1. Inject the AAV containing the CaMKII α Promoter (before training)




2. Be patient



3. Record or perform *in vivo* experiment


Channelrhodopsin-expressing mPFC neurons exhibit robust photo-excitation



An Optogenetic approach to this question

- 4 days of “shock” training


- On day 5, ChR stimulation in the PLCx (@1 Hz) throughout the seek period




ChR-driven activation of prelimbic cortex decreases cocaine-seeking behavior




First series of controls:
Activation of prelimbic neurons *prior* to punishment has no effect on
the rat's seeking behavior







After the rats learned that they might be shocked, ChR activation reduces cocaine taking significantly




Prelimbic photostimulation decreases compulsive cocaine seeking only *after* Shock sessions




Long-access to cocaine decreases excitability of deep-layer cortical neurons




Shock-sensitive rats increase cocaine seeking and become like the shock-resistant



Baseline
 Halo control



Shock
 Halo after shock



An opportunity for a TMS study



Summary and conclusions

- ~30% of rats will self-administer cocaine despite negative consequences (SR rats).
- Neurons in the prelimbic region of the PFC are significantly less active following prolonged cocaine self-administration, with shock resistant rats having the least active.
- Activation of prelimbic neurons with channelrhodopsin decreases cocaine seeking and taking behavior in SR rats,
- Inhibition of prelimbic neurons in shock sensitive rats increases cocaine seeking after shock sessions, turning the SS rats into SR rats
- Therapeutic potentials by stabilizing and increasing prelimbic cortex function (TMS, etc.)

Acknowledgements

Lab Members

Past

Mark Ungless (ICL)

Stephanie Borgland (UBC)

Garret Stuber (UNC)

Scott Bowers (VCU)

Billy Chen

Kay Tye (MIT)

Manu Argilli

Bjorn Schilstrom (KI)

Current

Jon Britt

Lindsay De Biase

Nick Edwards

Beate Fingers

Said Kourrich

Ikue Kusumoto

Nathan Marchant

Ross McDevitt

Marco Pignatelli

Hau-Jie Yau

Stephanie Goddard

Steph Chung

Collaborations

Extramural

Rob Malenka

Karl Deisseroth

Feng Zhang

Howard Fields

Fred Ambroggi

Luis deLecea

Intramural

Jean Lud Cadet

Sergi Ferre

Brandon Harvey

Bruce Hope

Satoshi Ikemoto

Marisela Morales

Geoff Schoenbaum

Yavin Shaham

Roy Wise

Faiza Benaliouad

Thanks to NIDA and State of California